Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : FDA Sees Current COVID-19 Vaccine Protocol as Still Effective Ahead of Meeting on Pfizer, BioNTech Boosters

09/16/2021 | 10:38am EDT


© MT Newswires 2021
All news about PFIZER, INC.
05:06aBIONTECH : EMA - New manufacturing sites and new formulation approved for COVID-19 vaccine..
AQ
04:28aFDA May Soon Allow Mix-and-Match COVID-19 Booster Shots
MT
02:10aPFIZER : Federal COVID vaccine compensation up to $20,000
AQ
10/18MODERNA : U.S. FDA to allow mixing and matching of COVID-19 boosters- NYT
RE
10/18MODERNA : U.S. administers 408.8 mln doses of COVID-19 vaccines - CDC
RE
10/18PFIZER : How Pfizer's Warranty Program Gets Around Best Price?
AQ
10/18BIONTECH : EMA Issues Positive Opinion For New Formulation Of BioNTech/Pfizer COVID-19 Vac..
MT
10/18AML Hub continues to enhance global knowledge of acute myeloid leukemia throughout 2021
AQ
10/18OYSTER POINT PHARMA : drug becomes first FDA-approved nasal spray to treat dry eyes
RE
10/18IDEAYA BIOSCIENCES : Names Michael White as Chief Scientific Officer
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 101 M - -
Net income 2021 18 457 M - -
Net Debt 2021 29 308 M - -
P/E ratio 2021 12,2x
Yield 2021 3,82%
Capitalization 232 B 232 B -
EV / Sales 2021 3,22x
EV / Sales 2022 3,67x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 41,32 $
Average target price 45,72 $
Spread / Average Target 10,7%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.12.71%231 668
JOHNSON & JOHNSON1.74%421 513
ROCHE HOLDING AG17.78%342 644
NOVO NORDISK A/S56.38%238 110
ELI LILLY AND COMPANY41.54%216 655
MERCK & CO., INC.-5.68%195 296